Corvus Pharmaceuticals (CRVS) Earnings Dates, Call Summary & Reports

Compare

677 Followers

Earnings Data

Report Date

May 11, 2026

TBA (Confirmed)

Period Ending

2026 (Q1)

Consensus EPS Forecast

-0.15

Last Year’s EPS

-0.13

Same Quarter Last Year

Analyst Consensus

Strong Buy

Based on 5 Analysts Ratings

Earnings Call Summary

Q4 2025

Earnings Call Date:Mar 12, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presented multiple strong positives: robust early efficacy signals (notably cohort 4 AD results), durable responses without rebound, a clean safety profile across >150 patients, supportive biomarker data, favorable PTCL survival metrics versus historical controls, clear plans to expand into multiple indications, and a substantial $189M financing that increases pro forma cash to ~$246M providing runway into Q2 2028. Offsetting factors include materially higher R&D spending, continued quarterly net losses, reliance on small early cohorts pending larger confirmatory trials, timeline uncertainty for registrational data (primary Phase II AD mid-2027; PTCL full readout late 2027), and execution/regulatory risks inherent to multiple concurrent development programs. Overall, the positives (clinical signal, durability, safety, biomarker rationale, and strengthened balance sheet) outweigh the near-term financial and execution challenges, but success depends on upcoming larger trials and interim readouts.

Company Guidance

On the call management provided detailed financial and clinical guidance with numerous metrics: Q4 R&D expense was $9.9M (FY2025 $33.7M vs $19.4M in FY2024), Q4 net loss $12.3M (including a $0.7M non‑cash equity invest. loss), total stock‑comp $1.6M for the quarter, and year‑end cash, cash equivalents and marketable securities of $56.8M (vs $52.0M a year earlier); the company closed an upsized public offering that generated $189M net proceeds (also described as a ~$200M financing), bringing pro‑forma cash to ~$246M and extending the cash runway into Q2 2028. Clinical metrics and program timelines: soquelitinib cohort 4 showed mean EASI reduction 72% vs 40% placebo (p=0.035), 9/12 (75%) achieved EASI‑75 (+1 at EASI‑74), 25% EASI‑90, 33% IGA 0/1, 11/12 EASI‑50, with placebo EASI‑75 ~20% (or 17% adjusted) and two placebo patients needing rescue; in patients with prior systemic therapy, 0/7 placebo vs 3/5 (60%) active hit EASI‑75. Development plans and readouts: a randomized Phase II AD trial (200 patients; 4 cohorts of 50; doses 200 mg QD, 200 mg BID, 400 mg QD and placebo; 12‑week treatment + 90‑day follow‑up; primary endpoint median % EASI reduction) was initiated with data expected mid‑2027; Angel’s China Phase Ib/II (48 pts initial; 100 mg BID, 200 mg QD, 200 mg BID, 400 mg QD; potential +60–90 pts) should report initial data late this year; PTCL Phase III enrollment continues with an interim analysis later this year (Phase I 200 mg BID showed median PFS 6.2 months and median OS 28 months vs historical chemo PFS <3.5 months and OS <1 year); planned Phase II HS (~60 pts; 200 mg BID, 400 mg QD, placebo; 12 weeks; HiSCR50/75 endpoints) and an asthma study (~150 pts for 3 months) targeted later in 2026, and biomarker/durability signals (Treg increase, ↓IL‑4/IL‑5/IL‑17, small ↓TARC, maintained responses out to ~90–118 days post‑treatment) underpin expansion plans.

Strong Cohort 4 Efficacy in Atopic Dermatitis

Cohort 4 (n=12) showed a mean percent reduction in EASI of 72% versus 40% for placebo (p=0.035). 75% (9/12) achieved EASI-75 (one additional patient EASI‑74), 25% achieved EASI-90, 33% achieved IGA 0/1, and 92% (11/12) achieved EASI-50. Placebo EASI-75 was ~20% (17% if adjusted for missed visit patients).

Durable Responses with No Rebound

Responses were maintained out to 90 days post-treatment (observed in cohorts 3 and 4) with over 90% of patients not relapsing in the follow-up period, suggesting durable remission and a potential for intermittent dosing strategies.

Favorable Safety Profile and Viral Risk Data

No new safety signals in cohort 4 or across the Phase I program: no hepatic abnormalities, similar minor infection rates versus placebo, and no evidence of EBV reactivation in >150 patients representing >14,000 patient-days of exposure, including long-term treatment (>2 years in some patients).

Biomarker Support for Mechanism of Action

Biomarkers show decreases in IL-4, IL-5 and IL-17, a small reduction in TARC, reduced Th2 cells and an increase in regulatory T cells (Tregs), supporting ITK inhibition-mediated immune rebalancing and providing translational rationale for multiple inflammatory indications.

Progressing Clinical Development Across Multiple Indications

Initiated a randomized Phase II atopic dermatitis trial (200 patients, 4 arms; doses: 200 mg QD, 200 mg BID, 400 mg QD, placebo; 12-week treatment + 90-day follow-up) with data anticipated mid-2027; ongoing Phase III PTCL enrollment with an interim analysis later this year; planned Phase II trials for hidradenitis suppurativa (~60 patients) and asthma (~150 patients) later this year; Angel Pharmaceuticals conducting a blinded Phase Ib/II AD trial in China with initial cohort results expected late this year.

Positive Phase I/Ib PTCL Signal vs Historical Controls

Phase I/Ib PTCL results (200 mg BID cohort) showed median progression-free survival (PFS) of 6.2 months and median overall survival (OS) of 28 months, comparing favorably to historical chemotherapy PFS <3.5 months and median OS <12 months.

Strengthened Financial Position via Upsized Financing

Closed an upsized underwritten public offering in January that generated net proceeds of $189 million; cash, cash equivalents and marketable securities were $56.8 million at Dec 31, 2025 (vs $52.0M at Dec 31, 2024, ≈+9.2%), and pro forma cash including the financing was ~ $246 million, extending the cash runway into Q2 2028 and beyond key planned data readouts.

Corvus Pharmaceuticals (CRVS) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRVS Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
May 11, 2026	2026 (Q1)	-0.15 / -	-0.13	―	―	―
Mar 12, 2026	2025 (Q4)	-0.13 / -0.15	-0.18	16.67% (+0.03)	―
Nov 04, 2025	2025 (Q3)	-0.13 / -0.12	-0.6	80.00% (+0.48)	―
Aug 07, 2025	2025 (Q2)	-0.13 / -0.10	-0.07	-42.86% (-0.03)	―
May 08, 2025	2025 (Q1)	-0.12 / -0.13	-0.12	-8.33% (-0.01)
Mar 25, 2025	2024 (Q4)	-0.12 / -0.18	-0.14	-28.57% (-0.04)	―
Nov 12, 2024	2024 (Q3)	-0.11 / -0.60	-0.12	-400.00% (-0.48)	―
Aug 06, 2024	2024 (Q2)	-0.12 / -0.07	-0.14	50.00% (+0.07)	―
May 06, 2024	2024 (Q1)	-0.14 / -0.12	-0.17	29.41% (+0.05)	―
Mar 19, 2024	2023 (Q4)	-0.12 / -0.14	-0.21	33.33% (+0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRVS Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Mar 12, 2026	$16.01	$15.32	-4.31%
Nov 04, 2025	$7.64	$7.53	-1.44%
Aug 07, 2025	$4.13	$4.31	+4.36%
May 08, 2025	$3.35	$4.43	+32.24%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Corvus Pharmaceuticals Inc (CRVS) report earnings?

Corvus Pharmaceuticals Inc (CRVS) is schdueled to report earning on May 11, 2026, TBA (Confirmed).

What is Corvus Pharmaceuticals Inc (CRVS) earnings time?

Corvus Pharmaceuticals Inc (CRVS) earnings time is at May 11, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRVS EPS forecast?

CRVS EPS forecast for the fiscal quarter 2026 (Q1) is -0.15.